Back to Search Start Over

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Authors :
Charles Swanton
Rosalie Fisher
Sakshi Gulati
Martin Gore
Marco Gerlinger
Claudio R. Santos
Aengus Stewart
Andrew Rowan
James Larkin
Ignacio Varela
Max Salm
Gordon Stamp
Nicholas Matthews
Steven Hazell
Adam Rabinowitz
Nicholas McGranahan
Pierre Martinez
Benjamin Phillimore
Bradley Spencer-Dene
Paul A. Bates
Sharmin Begum
David Nicol
Stuart Horswell
Lisa Pickering
P. Andrew Futreal
Universidad de Cantabria
National Institute for Health Research (UK)
Ministerio de Economía y Competitividad (España)
Rosetrees Trust
Breast Cancer Research Foundation
Royal Marsden NHS Foundation Trust
University College London
Medical Research Council (UK)
Cancer Research UK
European Research Council
European Commission
Source :
Nat Genet. 2014 Mar;46(3):225-33, Digital.CSIC. Repositorio Institucional del CSIC, instname, UCrea Repositorio Abierto de la Universidad de Cantabria, Universidad de Cantabria (UC)
Publication Year :
2014

Abstract

PMCID: PMC4636053.-- et al.<br />Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We applied multiregion exome sequencing (M-seq) to resolve the genetic architecture and evolutionary histories of ten ccRCCs. Ultra-deep sequencing identified ITH in all cases. We found that 73-75% of identified ccRCC driver aberrations were subclonal confounding estimates of driver mutation prevalence. ITH increased with the number of biopsies analyzed, without evidence of saturation in most tumors. Chromosome 3p loss and VHL aberrations were the only ubiquitous events. The proportion of C>T transitions at CpG sites increased during tumor progression. M-seq permits the temporal resolution of ccRCC evolution and refines mutational signatures occurring during tumor development.<br />C.S. and M. Gerlinger are supported by grants from Cancer Research UK Biomarkers and Imaging Discovery and Development Committee (BIDD), the Medical Research Council and the Seventh European Union Framework Programme, and C.S. is supported by the Breast Cancer Research Foundation and the Rosetrees Trust. We acknowledge the Ramón y Cajal program of the Ministerio de Economía y Competitividad, Spain, and Novartis for funding support for E-PREDICT clinical trials. This study was supported by researchers at the National Institute for Health Research Biomedical Research Centres at University College London Hospitals and at the Royal Marsden Hospital.

Details

Language :
English
Database :
OpenAIRE
Journal :
Nat Genet. 2014 Mar;46(3):225-33, Digital.CSIC. Repositorio Institucional del CSIC, instname, UCrea Repositorio Abierto de la Universidad de Cantabria, Universidad de Cantabria (UC)
Accession number :
edsair.doi.dedup.....110536728214a41f21714ee7957f7b6f